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Breast cancer is prone to metastasize to bone: around 80% of patients with advanced disease exhibit 
osteolytic bone metastases1,2. Once metastatic breast cells are in the bone marrow, they alter the functions 
of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells and hijack signals coming from 
the bone matrix1,2. Speciically, metastatic breast cancer cells enhance bone resorption and inhibit bone 
formation, which leads to skeletal destruction and subsequent occurrence of skeletal complications1. 
hese skeletal complications can be fatal or may rapidly impede the quality of life of patients by causing 
pathological fractures, hypercalcemia, nerve compression and loss of mobility2.
Bisphosphonates are bone-seeking drugs that inhibit osteoclast-mediated bone resorption2. hey are 
the standard of care for the prevention and treatment of skeletal complications in patients with malignant 
bone disease2. Additionally, a body of preclinical evidence suggests that bisphosphonates may act as anti-
tumor agents, able to inhibit tumor cell adhesion, invasion and proliferation in vitro3. Bisphosphonates 
also inhibit tumor growth in vivo through antiangiogenic, anti-invasive and immunomodulatory activ-
ities3–5. However, bisphosphonates bind avidly to bone mineral, which limits their bioavailability and 
therefore their direct antitumor potential in vivo2,6. his observation likely explains why high doses of 
bisphosphonates have oten been used in experimental studies. Unfortunately, due to renal toxicity, such 
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high doses are incompatible with the bisphosphonate dosing regimens that have been approved for the 
treatment of patients with bone metastases2.
Current advances in acoustic technology have made ultrasound a modality with therapeutic and diag-
nostic applications in oncology7,8. Ultrasound energy is a non-ionizing pressure wave that can produce 
both mechanical and thermal efects8. In this respect, high-intensity focused ultrasound has potential for 
tumor ablation, causing tissue necrosis through the conversion of mechanical energy into heat (up to 
80–90 °C within tissues) and inertial cavitation (that is formation and immediate and violent collapse of 
gas-illed bubbles)7,9,10. Mild temperatures (around 43 °C) called hyperthermia can also be created using 
ultrasound. Hyperthermia leads to increased blood low and enhanced vascular permeability and tumor 
oxygenation, promoting efectiveness of chemotherapy11. Ultrasound can also enhance local delivery of 
drugs or genes through stable cavitation (that is the sustained growth of cavitation bubbles and their 
oscillations over several acoustic cycles) and mostly inertial cavitation12. Stable cavitation is thought to 
enhance permeability of blood vessels by creating gaps between endothelial cells12. Ultrasound can also 
initiate the release of drugs from liposomes via inertial cavitation, which – through the rarefactional 
phase of an ultrasound wave - causes the expansion of a gas bubble followed by a violent collapse due to 
the inertia of the surrounding media. his collapse creates shock waves, which can disrupt the stability 
of co-localized liposomal drug carriers13. However, producing cavitation for drug/gene delivery without 
damaging tissues may be diicult to predict and control in vivo14,15. Interestingly, when used at a low 
intensity, pulsed ultrasound can enhance bone fracture repair by inducing a mechanical stress in bone, 
which in turn, stimulate the ossiication of a sot callus through the modulation of calcium ions chan-
nel16–19. Because bone destruction not only results from enhanced osteoclast-mediated bone resorption 
but also of inhibition of bone formation1, low-intensity ultrasound could be therefore an efective strategy 
in the treatment of bone metastasis to restore osteoblast functions20. he exact mechanisms leading to 
bone growth stimulated by low intensity pulsed ultrasound still need to be more thoroughly understood. 
Low-intensity ultrasound applied continuously might even enhance local delivery of bisphosphonates 
in skeletal tumors by creating mild hyperthermia and biomechanical efects, while avoiding cavitation.
Here, we sought to explore the efects of low-intensity continuous ultrasound as a strategy to force 
bisphosphonate penetration through tumor tissue using animal models of human breast cancer and bone 
metastasis. Results demonstrated signiicantly reduced bone destruction and slower tumor burden, both 
in bone and outside bone, when using ultrasound in combination with the bisphosphonate zoledronate.
Results
ȋȌȋȌin vitroǤ Isopentenyl 
pyrophosphate (IPP) accumulation is commonly used as a surrogate marker of bisphosphonate penetra-
tion in tumor cells21. Cells treated with PBS (vehicle) or HT alone did not accumulate IPP (Fig. S1A). No 
IPP accumulation was observed with a 1-hour treatment of ZOL, combined or not with HT (Fig. S1A). 
Accumulation of IPP in tumor cells was observed with a 24-hours treatment of ZOL (1054 ± 310 pmol/mg). 
If a 24-hours treatment of ZOL was combined with 30 minutes of HT a signiicant increase in the 
intracellular accumulation of IPP was observed when compared with ZOL alone (2002 ± 235 pmol/mg; 
p < 0.05) (Fig. S1A).
ȋȌȋȌin vitroǤ he 
bisphosphonate ZOL is a potent inhibitor of farnesyl pyrophosphate (FPP) synthase, a key enzyme in 
the mevalonate pathway3. As a result of the inhibition of FPP synthase, ZOL prevents the prenylation 
of small G-proteins (e.g., Ras, Rho and Rap1A), which are essential for cancer cell adhesion, migration 
and invasion, as it induces the intracellular accumulation of the ATP analogue isopentenyl pyrophos-
phate (IPP) in tumor cells3. Measurements of unprenylated small G-proteins (i.e., Rap1A) and IPP in 
ZOL-treated tumor cells have been therefore used as surrogate markers of bisphosphonate antitumor 
activity3.
he efects of ZOL and US on IPP accumulation in human MDA-MB-231/B02 breast cancer cells 
in vitro was examined by mass spectrometry (Fig. S1). B02 cells treated with PBS (the vehicle for ZOL) 
or US alone did not accumulate IPP. By contrast, a one-hour ZOL treatment in combination with US 
increased statistically signiicantly the intracellular accumulation of IPP in tumor cells, compared with 
either treatment alone (1,967 ± 882 and 109 ± 61 pmol/mg protein in US+ ZOL- and ZOL-treated tumor 
cells, respectively; P < 0.01). A 24-hours ZOL treatment in combination with US further increased 
intracellular IPP levels in tumor cells, compared with ZOL alone (7,500 ± 657 vs 3,200 ± 703 pmol/mg; 
P < 0.01) (Fig. S1). Combining US with ZOL allowed the highest accumulation of IPP compared to 
all other groups, including pure hyperthermia treatments (p < 0.05) (Fig. S1). Additionally, we found 
a strong correlation between IPP accumulation and unprenylation of Rap1A in B02 cells treated with 
ZOL, alone or in combination with US (Fig. 1). As shown by Western blotting, unprenylated Rap1A was 
undetectable in tumor cells treated only with US. Unprenylated Rap1A was barely detectable following 
a 1-h ZOL treatment of tumor cells. By contrast, when ZOL and US were combined to treat B02 cells 
for 1 hour a substantially enhanced accumulation of unprenylated Rap1A was observed (Fig. 1). A 24-h 
treatment with ZOL further increased accumulation of unprenylated Rap1A, irrespective of US (Fig. 1). 
However, given the short half-life of bisphosphonates in blood (approximately 1 hour), it is unlikely that 
cancer cells are exposed to a bisphosphonate for several hours in vivo.
www.nature.com/scientificreports/
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We previously reported that the activity of the mevalonate pathway in B02 cells was low compared 
with that of MCF-7 breast cancer cells4,5. As illustrated in Fig. 1, lovastatin (an inhibitor of HMG-CoA 
reductase, a mevalonate pathway enzyme upstream of FPP synthase) substantially increased unpreny-
lated Rap1A protein levels in MCF-7 cells. In sharp contrast, unprenylated Rap1A was undetectable in 
lovastatin-treated B02 cells. Nevertheless, the combined treatment of B02 cells with ZOL+ US did induce 
intracellular accumulation of unprenylated Rap1A in these tumor cells, further demonstrating that US 
maximized the antitumor efect of ZOL in B02 breast cancer cells in vitro.
Ǧ   ȋȌ     ǡ
   Ǥ Measurements performed with an hydrophone demonstrated 
that wideband emission, which is considered to be a signature for cavitation22, was not detected in cul-
tured B02 cells treated for 30 min with US (Fig. S4A), indicating that cavitation was not involved during 
sonication experiments. By contrast, a 30-min treatment of B02 cells with US induced mild hyperthermia 
(Fig. S4B). US-induced hyperthermia did not however afect B02 tumor growth at 24-h post-treatment, 
when used alone or in combination with ZOL (Fig. S5). Similar results were obtained with human 
MCF-7 or T47D breast cancer cells (Fig. S5).
As opposed to what was observed with ZOL+ US treatment (Fig. S1A), a 1-h treatment of B02 cells 
with ZOL under hyperthermic culture conditions (42 °C) created with warm water did not induce intra-
cellular accumulation of IPP (Fig. S1B and S1C). Similarly, Rap1A was barely detectable under these 
experimental conditions (Fig. S1C). hus, these results indicated that US not only induced hyperthermia 
but also mechanical stress, leading to drug uptake by tumor cells.
We next examined whether US generated similar bioefects (hyperthermia and/or cavitation) in vivo. 
he experimental device used to treat mice with US is depicted in Fig. S2C, the ultrasounds probe being 
focused on hind limbs of animals. US treatment of mice induced a mild hyperthermia in the hind limbs, 
whereas the temperature in the abdominal cavity remained unchanged (Fig. S4D). Examination of main 
organs (kidneys, liver, spleen, lungs, ovaries), at autopsy and then histologically, revealed that US treat-
ment did not cause any damage (data not shown). Additionally, US treatment did not induce acoustic 
cavitation in animals (Fig. S4E).
Ǧ  ȋȌ    ơ   ȋȌ  -
Ǥ We used a mouse model of human B02 
breast cancer bone metastasis in which animals display radiographic evidence of osteolytic lesions in 
hind limbs 18 days ater tumor cell inoculation23,24. We compared the efects of a single administration 
of ZOL (100 µ g/kg body weight), alone or in combination with US (applied single or daily), on the pro-
gression of established bone metastases by using a protocol in which treatment (ZOL and/or US) was 
administered to tumor-bearing mice on day 18 ater tumor cell inoculation. he dosing regimen of ZOL 
used in the present study was equivalent to the 4-mg clinical intravenous dose given to breast cancer 
patients with bone metastases.
Radiographic analysis on day 32 ater tumor cell injection revealed that tumor-bearing mice treated 
with a single dose of ZOL had osteolytic lesions that were 55% (P < 0.01) smaller than those of 
tumor-bearing mice treated with the vehicle (Fig.  2a and Table  1). Compared with vehicle, a daily US 
treatment of tumor-bearing animals did not inhibit bone destruction (Table 1). Similarly, tumor-bearing 
mice treated with a single injection of ZOL immediately followed by single US treatment had osteolytic 
lesions that were the same size as those of mice treated with ZOL only (Table 1). In sharp contrast, we 
Figure 1. Low-intensity continuous ultrasound (US) enhances the antitumor efect of the 
bisphosphonate zoledronate (ZOL) in vitro. B02 breast cancer cells were treated with 25-µ M ZOL for 1h, 
then cultured without drug for 23h. C-US was given for 30 min. B02 cells in culture also received a 24-h 
ZOL treatment, alone or in combination with C-US (30 min). Alternatively, B02 and MCF-7 breast cancer 
cells were treated with 5 µ M of the HMG-CoA reductase inhibitor lovastatin (LOV). Cells were harvested, 
lysed and protein extracts were electrophoresed then analyzed by western blotting for the presence of 
unprenylated and total Rap1A. Cropped gels are presented. Full-length blots are presented in Supplementary 
Figure 3. Tubulin was used as a control for equal protein loading. LOV-treated MCF-7 cells were used as a 
positive control.
www.nature.com/scientificreports/
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Figure 2. Efects of zoledronate (ZOL), alone or in combination with low-intensity continuous 
ultrasound (US), on the progression of established breast cancer bone metastases. (a) Radiographic 
analysis of hind limbs from B02 tumor-bearing mice treated with the vehicle, ZOL or the combination of 
ZOL with US. Arrows indicate osteolytic lesions. (b) Goldner’s trichrome staining of tissue sections of tibial 
metaphysis from metastatic legs. Bone is stained green whereas bone marrow and tumor cells (asterisk) are 
stained brown. (c) upper panels: tartrate-resistant acid phosphatase (TRAP) staining of bone tissue sections 
of metastatic legs from mice, showing osteoclast resorption surfaces (arrows). Bottom graph: Osteoclast 
resorption surface was calculated as the ratio of TRAP-positive trabecular bone surface to the total 
trabecular bone surface at the tumor-bone interface. All images were obtained from diferent mice on day 
32 ater tumor cell inoculation. he images shown are examples that best illustrate the efects of the diferent 
treatments on bone metastasis formation.
www.nature.com/scientificreports/
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found that tumor-bearing mice treated with a single injection of ZOL and receiving a daily treatment 
with US had osteolytic lesions that were 81% (P < 0.001) and 58% (P < 0.01) smaller than those of 
vehicle-treated and ZOL-treated animals, respectively (Table 1 and Fig. 2a).
Histomorphometric analysis of hind limbs with metastases showed that mice treated with ZOL had 
a statistically signiicant higher BV/TV ratio (bone volume/tissue volume; indicating prevention of bone 
loss) than vehicle-treated mice (Fig.  2b and Table  2). his diference was accompanied with a sharp 
reduction of the tartrate-resistant acid phosphatase (TRAP) staining of bone tissue sections of met-
astatic legs from ZOL-treated mice (indicating a reduction of active-osteoclast resorption surfaces at 
the tumor-bone interface) (Fig.  2c). By contrast, the BV/TV ratio and TRAP staining of hind limbs 
from animals treated with a daily application of US were similar to those observed with vehicle-treated 
animals (Table  2 and Fig.  2c). he use of US (single or daily application) in combination with ZOL 
did not further improve the BV/TV ratio, compared with the ZOL-treated group (Table 2). Similarly, a 
daily application of US in combination with ZOL did not statistically signiicantly further reduce TRAP 
staining, compared with that observed with ZOL alone (Fig. 2c). Importantly, the combined treatment 
of ZOL+ US decreased the TB/STV ratio (a measure of the skeletal tumor burden) by 76% (P < 0.01), 
compared with vehicle or US alone (Fig. 2b and Table 2). Additionally, a treatment with ZOL+ US was 
statistically signiicantly more efective than a treatment with ZOL alone (P < 0.01) at decreasing skeletal 
tumor burden (Fig. 2b and Table 2). hus, in addition to its therapeutic activity in preserving bone tissue, 
our histomorphometric data showed that ZOL had anticancer beneits in the treatment of experimental 
bone metastasis, when used in combination with US.
ȋȌǦȋȌǦ
          Ǥ 
To determine how ZOL+ US could decrease skeletal tumor burden, we measured the extent of vascular-
ization and tumor cell proliferation in hind limbs with metastases from mice treated with ZOL, alone 
Dosing regimens
Nber of 
mice mm2/mouse
P, compared with 
vehicle
P, compared 
with ZOL
Vehicle 10 6.5 ± 0.8 —
C-US (daily) 13 7.4 ± 1.3 0.60
ZOL 11 3.0 ± 0.4 < 0.001 —
ZOL+ C-US (single) 6 3.9 ± 0.9 0.03 0.30
ZOL+ C-US (daily) 14 1.3 ± 0.2 < 0.0001 < 0.001
Table 1.  Efect of diferent dosing regimens of zoledronic acid, alone or in combination with low-
intensity continuous ultrasound, on the progression of established breast cancer bone metastases, as 
judged by radiography*. *Data are mean values ± SD from two separate experiments. All measurements 
were made 32 days ater tumor cell injection. P values are for pairwise comparisons with the vehicle-treated 
control group or the ZOL-treated group using the nonparametric Wilcoxon test. ZOL = zoledronic acid;  
C-US = low-intensity continuous ultrasound; – = not applicable (referent).
Dosing regimens Nber of mice
Bone volume 
(BV/TV, %)
P, vs 
vehicle
P, vs 
ZOL
Tumor burden 
(TB/STV, %)
P, vs 
vehicle
P, vs 
ZOL
Naïve 4 30 ± 1 0
Vehicle 6 20 ± 3 — 62 ± 8 —
C-US, daily 5 19 ± 2 0.65 58 ± 6 0.35
ZOL 6 28 ± 4 0.04 — 46 ± 11 0.05 —
ZOL+ C-US, single 4 28 ± 3 0.03 0.93 32 ± 12 0.05 0.26
ZOL+ C-US, daily 10 29 ± 3 < 0.01 0.43 11 ± 6 < 0.01 < 0.01
Table 2.  Efect of diferent dosing regimens of zoledronic acid, alone or in combination with low-
intensity continuous ultrasound, on the progression of established breast cancer bone metastases, as 
judged by bone histomorphometry*. *Data are mean values ± SD from one representative experiment out 
of two. n is the number of mice. All measurements were made 32 days ater tumor cell injection. P values 
are for pairwise comparisons with the vehicle-treated control group or the ZOL-treated group using the 
nonparametric Wilcoxon test. Naive: histomorphometric values of hind limb from a naive mouse that did 
not receive any tumor cells or treatment is shown for comparison. ZOL = zoledronic acid; C-US = low-
intensity continuous ultrasound; BV/TV = bone volume-to-tissue volume ratio; TB/STV = tumor burden-to-
sot tissue volume ratio; – = not applicable (referent).
www.nature.com/scientificreports/
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or in combination with US. Immunohistochemical analysis of bone metastases with an anti-CD31 anti-
body that speciically recognizes murine endothelial cells showed that a single treatment with ZOL or a 
daily treatment with US did not inhibit tumor-associated angiogenesis, compared with vehicle (Fig. 3a). 
Similarly, ZOL or US treatment of metastatic animals did not afect tumor cell proliferation, as judged 
by Ki67 nuclear antigen staining of metastatic hind limbs (Fig.  3b). By contrast, ZOL in combination 
with US statistically signiicantly decreased both the vascularization and tumor cell proliferation by 70%, 
compared with ZOL alone (Fig. 3a,b).
To further demonstrate that US treatment was triggering the antitumor activity of ZOL, we meas-
ured unprenylated Rap1A levels in bone marrow protein extracts from metastatic hind limbs of animals 
treated with the vehicle or ZOL (alone or in combination with US). As shown by Western blotting 
(Fig. 3c), only ZOL+ US induced accumulation of unprenylated Rap1A in metastatic bone marrow. his 
accumulation of the unprenylated form of Rap1A was therefore indicative of the cellular uptake of ZOL 
and subsequent inhibition of FPP synthase activity.
ǦȋȌǤ 
To understand how US could trigger ZOL antitumor efects, we measured the binding of bisphospho-
nates by luorescence microscopy in tibias from animals treated with luorescently labeled risedronate 
(FAM-RIS), alone or in combination with US. As shown in Fig. 4, there was a 55% decrease of the luo-
rescence intensity in tibias from animals treated with FAM-RIS + US (P < 0.04), compared with animals 
treated with FAM-RIS alone. hus, US promoted the release of bisphosphonates from bone mineral, 
thereby explaining why there was an accumulation of unprenylated Rap1A in the bone marrow from 
metastatic animals treated with ZOL+ US (Fig. 4).
Ǧ  ȋȌ    ơ   ȋȌ  -
Ǥ here is evidence that primary breast tumors recruit 
bone marrow-derived endothelial cell progenitors that then diferentiate into mature endothelial cells and 
contribute to the vascularization of these tumors24. We therefore reasoned that, by promoting the release 
of bisphosphonates from bone mineral, US might assist ZOL in interfering with the vascularization of 
breast tumors. To address this question, immunodeicient mice bearing subcutaneous B02 breast tumor 
xenograts were treated with a single dose of ZOL (100 µ g/kg body weight), alone or in combination with 
US (daily). Alternatively, tumor-bearing mice received a daily application of US only. On the irst week of 
treatment (D8), ZOL or US alone did not inhibit B02 tumor growth (Fig. 5a). By contrast, a 42% reduc-
tion of the volume of B02 tumors (P < 0.002) was observed in ZOL+ US treated mice, compared with 
vehicle-treated animals (Fig. 5a). In addition, compared with ZOL-treated animals, the weight of tumors 
from animals treated with ZOL+ US was reduced by 34% at D8 (Fig. S7). he smaller size and weight of 
tumors from ZOL+ US-treated animals was associated with decreased tumor-associated angiogenesis, as 
judged by CD31 immunostaining (Fig. 5b). In situ immunodetection of the proliferation marker Ki-67 
nuclear antigen in tumors from mice treated with ZOL+ US showed also a substantial reduction in pro-
liferative index, compared with tumors from vehicle-treated mice (Fig. 5c).
On the second week of treatment (D15), the outgrowth of subcutaneous tumor xenograts in ZOL+ US 
treated animals was still statistically signiicantly lower compared with that of vehicle-treated animals 
(Fig.  5a). here was also a signiicant reduction of tumor-associated angiogenesis (Fig.  5b). However, 
this combined treatment did not anymore inhibit the proliferative index of B02 subcutaneous tumors 
(Fig. 5c). In addition, tumor weights between experimental groups did not anymore difer at D15 (Fig. 
S4). hus, the antitumor efect of ZOL that was observed ater a one-week treatment of animals with 
ZOL+ US did not persist ater two weeks of treatment. Given that a single dose of ZOL was administered 
to tumor-bearing animals, our results suggested that circulating levels of ZOL liberated from bone min-
eral gradually decreased over time, ZOL concentrations being too low at D15 to be efective on tumor 
growth inhibition. Importantly, this contention was supported by the observation that ZOL+ US induced 
accumulation of unprenylated Rap1A in tumor extracts at D8, contrary to D15 (Fig. 5d).
Discussion
Our results show that a single clinically relevant dose of ZOL produced meaningful antitumor efects 
in animal models of primary breast tumor and secondary bone metastasis, only when tumor-bearing 
mice were co-treated with ultrasound (US). In agreement with previous indings24, mice with estab-
lished bone metastases that were treated with a single clinical dose of ZOL had less bone destruction 
and less skeletal tumor burden, than vehicle-treated animals. his reduced skeletal tumor burden was 
likely due to the antiresorptive activity of ZOL. Indeed, the skeleton is a rich source of growth factors 
including transforming growth factor-beta (TGF-β ) and insulin-like growth factor (IGF) that are released 
during bone resorption1. By inhibiting bone resorption, bisphosphonates deprive tumor cells of these 
bone-derived factors that are required for tumor growth2,3,6,23,24. However, if bisphosphonate treatment 
decreased skeletal tumor burden solely by reducing bone loss, we would not have expected the treatment 
combining ZOL and US to have inhibited skeletal tumor burden more than what we observed with ZOL 
alone. hus, additional inhibitory mechanisms have happened when using a combined treatment with 
ZOL and US. In this respect, accumulation of unprenylated Rap1A was detected in skeletal tumors from 
animals treated with ZOL and US. his accumulation was indicative of the cellular uptake of ZOL and 
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Figure 3. Efects of zoledronate (ZOL), alone or in combination with low-intensity continuous 
ultrasound (US), on B02 skeletal tumor burden. (a) Quantiication of CD31-positive blood vessels within 
skeletal tumors. Right-hand panels: immunostaining of CD31-positive blood vessels (arrows) within skeletal 
tumors from animals treated with ZOL or ZOL + daily US. (b) Quantiication of tumor-cell proliferation, as 
judged by the percentage of Ki-67–positive nuclei. Right-hand panels: Ki-67 nuclear antigen immunostaining 
within skeletal tumors from animals treated with ZOL or ZOL + daily US. Proliferative cells are stained 
brown. (c) Immunodetection of unprenylated and total Rap1A in protein extracts from skeletal tumors 
of animals treated with the vehicle, ZOL or ZOL+US. Cropped gels are presented. Full-length blots are 
presented in Supplementary Figure 6. Tubulin was used as a control for equal protein loading. All data were 
obtained from diferent mice on day 32 ater tumor cell inoculation. he images shown are examples that 
best illustrate the efects of the diferent treatments on bone metastasis formation.
www.nature.com/scientificreports/
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subsequent inhibition of FPP synthase activity, demonstrating that US promoted ZOL penetration within 
tumors. In addition our results about pure hyperthermia experiments are also in agreement with the fact 
that hyperthermia increases cell membrane permeability and therefore drug uptake11,12. Importantly, IPP 
accumulation and Western Blot analysis demonstrated that US inducing both mechanical and thermal 
efects were more eicient to promote ZOL penetration into tumor cells than hyperthermia alone. US 
create heat and mechanical stress, including radiation force efects, acoustic streaming, standing waves 
and Lamb wave25. For example, Lamb waves propagate along the surface of solid materials such as bone 
surfaces25. As demonstrated here using luorescent risedronate, it is therefore likely that some of these 
mechanical stresses generated by US mechanically forced the release of ZOL from the bone surface, ena-
bling a continuous impregnation of the bone marrow with low iterative bisphosphonate concentrations, 
which in turn impeded skeletal tumor outgrowth. his contention was supported by the substantially 
decreased tumor-associated angiogenesis and tumor cell proliferation in situ when ZOL+ US treatment 
was applied.
here is evidence that primary breast tumors recruit bone marrow-derived endothelial cell pro-
genitors that then diferentiate into mature endothelial cells and contribute to the vascularization of 
Figure 4. Efects of continuous ultrasound on the binding of luorescent bisphosphonate FAM-RIS to 
bone in vivo. FAM-RIS (BP) was injected into the tail vein of mice (0.35 mg/kg). Mice were then treated 
or not treated with low intensity continuous ultrasound (C-US) for 2 weeks. (a) Representative images 
of Goldner trichrome stained tibial tissue sections and corresponding bone tissue sections examined 
by luorescence using episcopic light. (c) Quantiication of the binding of FAM-RIS. Both intensity of 
luorescence and bisphosphonate-binding area were quantiied. All results are presented as the ratio between 
luorescence or bisphosphonate binding area and the bone volume. Let graph: Intensity of luorescent 
bisphosphonate over bone volume ratio (IDV/BV). Right graph: Fluorescent bisphosphonate binding-area 
over bone volume ratio (BPf/BV).
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Figure 5. Efects of zoledronate (ZOL), alone or in combination with low-intensity continuous 
ultrasound (US), on the growth of established subcutaneous breast tumors. (a) B02 breast cancer cells 
were implanted subcutaneously into immunodeicient mice. Ater subcutaneous tumors reached a volume 
of 30 mm3, mice were treated with the vehicle, ZOL, US or ZOL+ US (day 1). Tumor progression was 
monitored from day 1 (D1) to day 15 (D15), following measurement of the tumor volume with a Vernier 
caliper. (b) Quantiication of CD31-positive blood vessels within subcutaneous tumors at D8 and D15. 
Upper panels: immunostaining of CD31-positive blood vessels within tumors from animals treated with 
ZOL or ZOL + daily US. (c) Quantiication of Ki-67–positive tumor cells within subcutaneous tumors at D8 
and D15. Upper panels: Ki-67 nuclear antigen immunostaining within subcutaneous tumors from animals 
treated with ZOL or ZOL + daily US. (d) Immunodetection of unprenylated Rap1A in protein extracts 
from subcutaneous tumors at D8 and D15. Cropped gels are presented. Full-length blots are presented in 
Supplementary Figure 8. Tubulin was used as a control for equal protein loading. *, **P < .05 and .002, 
respectively.
www.nature.com/scientificreports/
1 0SCIENTIFIC REPORTSȁ ?ǣ ? ? ? ? ?ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?
these tumors24. Bisphosphonates exhibit anti-angiogenic properties in vitro and in vivo, and they reduce 
tumor-associated angiogenesis in animal models of cancer3. We therefore reasoned that, by promoting 
the release of bisphosphonates from bone mineral, US might assist ZOL in interfering with the vascu-
larization of breast tumors. To address this question, we conducted experiments in mice bearing breast 
tumors outside bone (i.e. subcutaneous tumor xenograts) that were treated with the vehicle or ZOL, 
alone or in combination with US. We found that US in combination with a single clinical dose of ZOL 
inhibited subcutaneous tumor growth, compared with ZOL alone or the vehicle. Additionally, tumor 
growth reduction coincided with decreased tumor-associated angiogenesis and decreased tumor cell 
proliferation. Importantly, there was also an increased accumulation of unprenylated Rap1A in subcuta-
neous tumors, demonstrating that there was an uptake of ZOL within these tumors. he bone marrow 
is a reservoir for CD11b+ myelomonocytic cells3. Bone marrow-derived CD11b+ myelomonocytic cells 
iniltrate distant tumors and contribute to their vascularization by producing matrix metalloprotease-9, 
which in turn, promotes the release of VEGF from the extracellular matrix26. It has been previously shown 
that treatment of animals with high cumulative doses of ZOL (0.1 mg/kg, daily for 4 weeks) inhibits the 
iniltration of CD11b+ myelomonocytic cells within mouse mammary tumors26. By inducing the release 
of ZOL from the bone matrix with US, it is likely that a single dose of this bisphosphonate (0.1 mg/
kg) also inhibited the iniltration of proangiogenic CD11b+ myelomonocytic cells within human breast 
tumors. As discussed above, ZOL might also interfere with the recruitment of bone marrow-derived 
endothelial progenitors to distant tumors. he net result was that ZOL exhibited a systemic antitumor 
efect when combined with US by reducing tumor-associated angiogenesis. However, this antitumor 
efect of ZOL disappeared over time, suggesting that bisphosphonate concentrations released from bone 
mineral (upon US treatment) gradually decreased, and became too low to be efective on inhibition of 
tumor growth outside bone.
Our results do, to some extent, echo the indings observed in the clinical use of bisphosphonates as 
adjuvant therapy in breast cancer. Large phase-III clinical trials have shown that adding ZOL to endo-
crine therapy or chemotherapy improves disease-free survival of patients with endocrine-responsive early 
breast cancer in a low estrogen environment (i.e., following ovarian suppression therapy or in women 
with established menopause at diagnosis)2. For example, the landmark Austrian Breast and Colorectal 
Study Group (ABCSG)-12 trial showed that the addition of ZOL to hormone therapy for 3 years reduced 
the risk of disease progression by 36% in premenopausal women with endocrine-responsive stage I or II 
breast cancer, who were also receiving goserelin to induce artiicial menopause2. Interestingly, women in 
the ABCSG-12 trial who received ZOL maintained improvements in relapse-free survival at 84 months’ 
follow-up and there was also a signiicant reduction in the risk of death, while their treatment lasted 
more than 3 years ago2. his “carryover” efect of ZOL in the ABCSG-12 trial may be explained by the 
pharmacological properties of bisphosphonates. It is sustained by our own experimental data, suggesting 
that the release of ZOL from the skeleton (either naturally or US-induced) enables continuous impregna-
tion of the bone marrow with low iterative bisphosphonate doses that may impede the retention of cancer 
cells in the bone marrow and/or interfere with the tumor-growth supportive functions of bone-derived 
factors and bone marrow-derived myelomonocytic cells and endothelial cell progenitors. Additionally, 
our present indings suggest that US may be an efective strategy to enhance bisphosphonate penetration 
through tumor tissue. ZOL treatment concurrent with neo-adjuvant chemotherapy has been reported 
to improve pathologic complete response in patients with breast cancer, compared with chemother-
apy alone27. US-induced regional hyperthermia has been shown to increase the beneit of neo-adjuvant 
chemotherapy in patients with localized sot-tissue sarcoma11. It is conceivable that an appropriate focus-
ing of the US beam to breast tumors in patients receiving neoadjuvant chemotherapy and ZOL would 
enhance pathologic complete response rate. In the current study the observed efect comes in part from 
mechanical stress on bone cells, potentially surface waves that propagate along the bone surface. his 
hypothesis also makes the results of the cell culture experiments relevant, since the cells are seeded on 
a rigid petri dish surface, similarly to the way cells are located within the bone. However, the depth of 
penetration of the surface wave is on the order of the Lamb wavelength in the bone, which, in case of 
the mouse bone, can cover the entire bone thickness. In a human bone ultrasound will propagate mostly 
supericially through cortical bone3. herefore, adjustments of the ultrasound transducer geometry and 
treatment parameters will be performed in order to reach the trabecular bone and the bone marrow in 
a human bone.
In conclusion, our results demonstrate the potential of low intensity ultrasound as an efective strat-
egy to force bisphosphonate desorption from bone and its penetration through tumor tissue, enabling 
bisphosphonate antitumor activity (both in bone and outside bone). Our indings made US a promising 
modality in oncology to trigger anticancer therapy with bisphosphonates.

ǡ    Ǥ Zoledronate [1-hydroxy-2-(1H-imidazole-1-yl)
ethylidene-bisphosphonic acid], as disodium salt, was provided by Novartis Pharma AG (Basle, 
Switzerland). Carboxyluorescein-risedronate (FAM-RIS) was provided by Dr Hal Ebetino (Procter & 
Gamble Pharmaceuticals, Inc., Mason, OH, USA). Zoledronate and FAM-RIS were dissolved in PBS 
(pH 7.4, Invitrogen).
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Human breast cancer cell lines MCF-7 and T47-D were obtained from the ATCC (American Type 
Culture Collection) and used within 6 months. Human B02 breast cancer cells, a subpopulation of the 
MDA-MB-231 cell line, were prepared as described previously4,5. he MDA-MB-231 and B02 cell lines 
were authenticated using short tandem repeat analysis. B02 and T47-D cells were cultured in Dulbecco’s 
Modiied Eagle’s Medium (Invitrogen) supplemented with 10% (v/v) fetal bovine serum (Invitrogen) 
and 1% (v/v) penicillin/streptomycin (Invitrogen). MCF-7 cells were cultured in EMEM medium (LGS 
Standards for ATCC) supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) penicillin/streptomycin 
and 10 µ g/mL insulin (Sigma-Aldrich). All cell lines were maintained at 37 °C in a 5% CO2 humidiied 
incubator.
Four-week-old female BALB/c athymic (nu/nu) mice were purchased from Janvier (St Berthevin, 
France). Animals were maintained in a 12-h light-dark cycle and given free access to food and water. 
All procedures involving animals, including the method by which they were culled and experimental 
protocols were conducted in accordance with a code of practice established by the ethical committee of 
the University of Lyon.
 Ǥ Sonication was generated with a lat, piezocomposite air-backed transducer of 
40 mm in diameter and with a resonance frequency of 2.9 MHz (Imasonic, Voray-sur-l’Ognon, France). 
he transducer was inserted into a sterile polyurethane cover (CIV-Flex Transducer cover, CIVCO, 
Kalona, IA) that was illed with degassed water. his cover attenuated the ultrasound pressure by about 
2%, when using a frequency of 2.9 MHz. A peristaltic Masterlex pump (L/S model 7518–60, Cole-Parmer 
Instruments Co., Chicago, IL) was used to maintain a continuous low (0.3 l/min) of the degassed water at 
20 °C, enabling the cooling of the transducer during in vivo experiments. he transducer-driving equip-
ment was composed of a power ampliier (Kalmus model 150 CF, Engineering International, Woodinville, 
WA) driven by an HP 8116A wave generator (Hewlett Packard GmbH, Boblinger, Germany). A NAP 
wattmeter/relectometer (Rohde & Schwarz, Munich, Germany) itted with its NAP-Z7 probe (Rohde & 
Schwarz, Munich, Germany) was used to measure forward and reverse electrical power. he wattmeter 
and the wave generator were connected to a laptop using a GPIB connection.
  ǦǤ Sonication 
was delivered in a continuous mode. he duration of each sonication was 30 minutes. Heat created in 
tissues by ultrasound is directly linked to the acoustic energy, heat difusion in tissues and perfusion28. 
Adequate acoustic parameters are a trade-of between temperature increase due to the absorption of 
acoustic energy and temperature decrease due to perfusion and heat difusion. herefore, an acoustic 
power of 12.8 watts was irstly delivered for 7 minutes in order to slightly increase the temperature at the 
bone-tissue interface up to 43 °C. hen the acoustic power is modulated as a function of time (10.2 W for 
2 minutes, 8.2 W for 4 minutes, 8.6 W for 2 minutes and 30 seconds and 8.2 W for the remaining 14 min-
utes and 30 seconds) to maintain hyperthermia (Fig S2A and S2D). hese settings were determined from 
previous numerical simulations using an in-house sotware29,30 as well as in vitro and in vivo experiments 
described below. he acoustic-power output and the maximal pressure amplitude as a function of the 
applied radiofrequency power were measured as described previously31. Under these experimental con-
ditions, the maximal peak negative-pressure amplitude calibrated in water was 0.29 MPa. hese settings 
were deined to avoid cavitation while creating hyperthermia and direct mechanical forces.
Previous to therapeutic experiments, these exposure conditions were tested in vivo in three mice to 
demonstrate that creating and maintaining mild HT in hind limbs will be feasible in real conditions 
without creating any complications or secondary lesions. For this purpose, mice were previously anes-
thetized with isolurane gas (4%) and maintained in that condition for the length experiment (isolurane 
1%, oxygen 100 mL/min). Two thin thermocouples (0.33 mm in diameter, MT-29, Physitemp, NJ, USA) 
were used. One was placed in hind limbs at the bone tissue interface and the other one in the abdominal 
cavity to check temperature increase produced with these parameters. his study was performed as part 
of diferent experiments for other purposes. Animal experiments were performed under an approved 
research protocol. hese experiments conformed to the requirements of the local oice of animal exper-
imentation were in accordance with the legal conditions of the French National Commission on Animal 
(N314, BH2012-06, BH2010-45).
In sot tissues, the force is applied in the direction of wave propagation and the magnitude of the 
force can be approximated by:
α
= =F
W
c
I
c
2absorbed
where F [dyn/(1000 cm)3 or kg/(s2cm2)] is the acoustic radiation force, Wabsorbed [W/(100 cm)
3] is the 
power absorbed by the medium at a given spatial location, c (m/s) is the speed of sound in the medium, 
α (Np/m) is the absorption coeicient of the medium and I (W/cm2) is the temporal average intensity at 
a given spatial location. he spatial distribution of the radiation force ield is, thus, determined by both 
the transmitted acoustic parameters and the tissue properties.
For the sonication of cultured tumor cells, Petri dishes were placed on an ultrasound absorber (RTV 
143, Rhone Poulenc, Milano, Italy) that was previously coated with ultrasound coupling gel to prevent 
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relection of ultrasound. he transducer and thermocouple were then dipped directly into the cell cul-
ture medium. Temperature of each thermocouple was registered every minute. Cavitation was measured 
using an hydrophone (ONDA HNR-1000, Sunnyvale, CA) placed near the ultrasound transducer point-
ing towards the exposed medium.
For in vivo experiments, the transducer was positioned directly into contact with mice ater applying 
acoustic gel (Ablasonic® , EDAP, Vaux-en-Velin, France) to avoid air between the transducer and the skin. 
Anesthetized mice were placed in dorsal decubitus position on an ultrasound absorber. For hyperther-
mia measurement, thermocouples were implanted in the abdominal cavity and the hind limb muscles of 
mice. Temperature of each thermocouple was registered every thirty seconds. Cavitation was measured 
using the same methodology as aforementioned.
ƪȋ	ǦȌǤ Five-week-old 
mice were injected intravenously with 0.35 mg/kg FAM-RIS or 0.1 ml PBS (vehicle)32. For measurement 
of luorescence background in bones, control mice received the vehicle only. Mice were then followed 
until day 13 or treated with US everyday, during 13 days. Mice were culled and hind limbs were collected 
and ixed in 70% ethanol, then embedded in methylmethacrylate. Undecalciied sections of long bones of 
7-µ m-thick were cut using a heavy duty microtome (Leica SM2500, Germany) equipped with tungsten 
carbide knife and stained with Goldner’s trichrome. Images were taken with episcopic luorescence light 
using Zeiss Axio Imager (Iena, Germany) equipped with Filter Set 09 (excitation BP 450–490, beamsplit-
ter FT 510, emission LP 515). Intensity of luorescence and the area of luorescent bisphosphonate were 
chosen as two parameters to assess bisphosphonate release related to ultrasonic treatment and measured 
by ImageJ sotware. Bone volume was also measured using ImageJ sotware. Results are presented as 
a ratio of intensity on bone volume and bisphosphonate volume on bone volume. Experiments were 
carried out in accordance with the approved guidelines and approved by the ethical committee of the 
University of Lyon (n°DR2014-12).
        Ǧ 
Ǥ Sonication was generated with a lat, piezocomposite air-backed transducer of 40 mm in 
diameter and with a resonance frequency of 2.9 MHz (Imasonic, Voray-sur-l’Ognon, France). Sonication 
was delivered in a continuous mode. he duration of each sonication was 30 minutes. he acoustic-power 
output and the maximal pressure amplitude as a function of the applied radiofrequency power were 
measured as described previously33,34. See Supplementary Materials and Methods for further details 
regarding the in-vitro and in-vivo experimental conditions for sonication and measurement of hyper-
thermia induced by low-intensity continuous ultrasound.
Ǥ he bone metastasis experiments in mice were 
conducted as previously described using B02 breast cancer cells23,24. In this model, mice usually develop 
bone metastases 18 days ater tumor cell injection, as judged by radiography. Osteolytic lesions were 
identiied on radiographs as demarcated radiolucent lesions in the bone. he area of osteolytic lesions 
was measured and the extent of bone destruction per mouse was expressed in square millimeters. Mice 
were analyzed by radiography on day 18, and tumor-bearing animals were distributed among the dif-
ferent treatment groups (n = 5–9 mice per group) Anesthetized mice were euthanized by cervical dis-
location ater radiography on day 32. Experiments were carried out in accordance with the approved 
guidelines and approved by the ethical committee of the University of Lyon (n BH2010-45).
Ǥ Subcutaneous tumor xenograt exper-
iments in mice were conducted using B02 breast cancer cells as previously described4,5. When B02 tum-
ors had reached a volume of 30 mm3, mice were randomly assigned to the diferent treatment groups 
(n = 7–8 mice/group). Tumor size was calculated by external measurement of the width (m1) and length 
(m2) of subcutaneous tumors using a Vernier caliper. Tumor volume (TV) was calculated using the 
equation TV = (m1
2 × m2)/2. Experiments were carried out in accordance with the approved guidelines 
and approved by the ethical committee of the University of Lyon (n°BH2012-06).
ȋȌǡȋȌǦ-
 ȋȌ      Ǧ Ǥ T47D, MCF-7, and B02 breast 
cancer cells were seeded in 10-cm Petri dishes at 2 × 106 cells/dish overnight at 37 °C in a 5% CO2 incu-
bator. Cells were treated with 25-µ M ZOL for 1h, then incubated without drug for 23 hours. Alternatively, 
cells in culture received a continuous treatment with ZOL for 24 hours. For ultrasound experiments, 
tumor cells previously treated with ZOL or let untreated were sonicated at room temperature for 30 
minutes. US-treated cells were then incubated at 37 °C for the rest of the experiment. For hyperther-
mia experiments, MDA-MB-231/B02 cells were seeded into lasks at 1 million cells/lask. Flasks were 
immersed during 30 minutes into a warm bath (43 °C) and then incubated for the rest of the experiment. 
Hyperthermia was generated only in vitro. It would have been diicult to induce pure hyperthermia only 
for small and deep areas in bone with a non-invasive technique that could have been properly compared 
with ultrasound conditions.
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Animals that had developed bone metastases were treated with a single dose of ZOL by subcutane-
ous injection in 100 µ L PBS (vehicle) on day 18 ater tumor cell inoculation. ZOL treatment was also 
administered to animals bearing subcutaneous tumors when these tumors reached a volume of 30 mm3. 
Based on an average body weight of 20 g for 4-week-old mice, ZOL was administered to tumor-bearing 
mice at a dosage of 100 µ g/kg, which was calculated equivalent to the 4-mg clinical dose24. Additionally, 
tumor-bearing mice that were treated with ZOL or the vehicle received a single or a daily 30-min treat-
ment with US. Control tumor-bearing mice received a treatment with vehicle only. All of the mice were 
sacriiced 2 weeks ater the beginning of the treatment.
    ȋȌǤ Bisphosphonate-induced IPP production was 
measured in human breast cancer cells, as previously described4,5. ZOL is an inhibitor of farnesyl pyro-
sphosphate synthase (FPPS) in the signaling mevalonate pathway. FPPS inhibition leads to the accumu-
lation of IPP. Bisphosphonate-induced IPP production was measured in MCF-7 breast cancer cells, as 
previously described35. IPP is thus a surrogate marker for ZOL penetration and action on the mevalonate 
pathway36. Following bisphosphonate treatment, alone or in combination with ultrasound, tumor cells 
were harvested by scraping, washed in PBS and extracted using ice-cold acetonitrile (300 µ L) and water 
(200 µ L). Samples were then concentrated using a Savant Speed Vacuum concentrator and reconstituted 
within 100 µ l of hexylalmine formate bufer containing 0.25-mM NaF and Na3VO4 (to prevent IPP 
degradation) and 1 µ M methyleneadenosine 5′ -triphosphate (AppCp), as internal standard. IPP in cell 
extracts was then quantiied by high-performance liquid chromatography negative ion electrospray ion-
ization mass spectrometry (Waters Micromass® ZQ™ Single Quadrupole). IPP calibrator and AppCp 
internal standard were purchased from Sigma (St. Louis, MO, USA). Quantiication of proteins was made 
using Bradford method and Bradford reagent (Sigma-Aldrich).
    ?    ? Ǥ In order to determine the efects 
of ZOL, US and lovastatin on the intracellular accumulation of unprenylated Rap1A protein, tumor cells 
in culture were lysed in 200 µ L RIPA bufer (Sigma-Aldrich) containing a cocktail of protease inhibitors 
(AEBSF 104 mM, aprotinin 80 µ M, bestatin 4 mM, E-64 1.4 mM, leupeptin 2 mM, pepstatin A 1.5 mM, 
dilution: 1/100, Sigma). For bone metastasis, the bone marrow of metastatic hind limbs was lushed 
with culture medium, bone marrow cells were then pelleted by centrifugation and cell pellets were lysed 
in RIPA bufer. Subcutaneous tumors were minced with a scalpel, homogenized with a homogenizer 
(Polytron PT 6100) and samples were lysed in RIPA bufer. Lysates (50-µ g protein/sample) from bone 
metastasis and subcutaneous tumors were then electrophoresed under reducing conditions on 4-12% 
SDS-polyacrylamide gels (Life Technologies) and electrophoresed proteins were then transferred onto 
polyvinylidene diluoride (PVDF) membranes (Merck Millipore). Membranes were irst incubated for 
1 hour with 5% (w/v) skimmed milk in TBS bufer containing 0.1% (v/v) Tween 20 to block nonspe-
ciic antibody binding. hese membranes were then incubated overnight at 4 °C with a goat-polyclonal 
anti-Rap1A antibody (SantaCruz Biotechnology) targeting the unprenylated form of the small GTPase 
Rap1A21, or an anti-mouse anti-Rap1A monoclonal antibody (SantaCruz Biotechnology), or a α -tubulin 
mouse monoclonal antibody (Sigma) diluted, respectively, to 1/500 and 1/2,000 in TBS-0.1% (v/v) Tween 
20 containing 5% (w/v) skimmed milk. Ater incubation with primary antibodies, membranes were 
washed then incubated with horseradish peroxide (HRP)-conjugated donkey anti-goat, (HRP)-conjugated 
goat anti-mouse (SantaCruz Biotechnology, 1/2,000 dilution) and anti-mouse secondary antibodies 
(Amersham; 1/2,000 dilution), and immunostaining was performed with enhanced chemiluminescence 
(ECL) detection system (Perkin Elmer LAS Inc.)21. All western blots were realized using samples deriving 
from a same experiment and all were performed in the same conditions.
Ǥ Following treatment with ZOL and/or US, tumor cells were further cultured for 
24 hours at 37 °C in a 5% C02 incubator, at which time cells were harvested by trypsinization and viable 
cells were counted under a microscope using the trypan blue exclusion method.
ǡǦȋȌǤ 
Bone histology, histomorphometric analysis and TRAP straining of bone tissue sections were performed 
as previously described23,24. Histomorphometric measurements (i.e., bone volume to tissue volume [BV/
TV] and tumor burden to sot tissue volume [TB/STV] ratios) were performed in a standard zone of 
the tibial metaphysis, situated at 0.5 mm from the growth plate, including cortical and trabecular bones. 
he BV/TV ratio represents the percentage of bone tissue. he TB/STV ratio represents the percent-
age of tumor tissue. he in situ detection of osteoclasts was performed on TRAP-stained longitudi-
nal parain-embedded medial sections of tibial metaphysis with the use of a commercial kit (Sigma). 
Osteoclast resorption surface was calculated as the ratio of TRAP-positive trabecular bone surface to the 
total trabecular bone surface at the tumor-bone interface.
Ǥ Immunohistochemistry was performed on an automated immunostainer 
(Ventana Discovery XT, Roche, Meylan, France) using DABmap Kit according to the manufacturer’s 
instructions. Staining was visualized with DAB solution with 3,3′ -diaminobenzidine as a chromo-
genic substrate. he sections were counterstained with Gill’s hematoxylin. 4-µ m tissue sections were 
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preincubated with 1% goat serum then incubated with a rabbit polyclonal anti-CD31 antibody (AnaSpec, 
Fremont). To measure tumor-cell proliferation, tumor sections were incubated with a rabbit polyclonal 
anti–Ki-67 antibody (MIB-1, Dako, Trappes, France). Image analysis was performed by using a light 
microscope (Eclipse E400, Nikon France, Champigny, France) equipped with a tri-CDD video camera 
(Sony, Japan). Tumor microvessel density was quantiied, as previously described4,5. he mitotic index 
was expressed as the percentage of Ki-67–positive nuclei. Ki67 analysis was performed using Histolab® 
sotware (Microvision Instruments, Evry, France).
Ǥ All data were analyzed using GraphPad Prism (La Jolla, USA). For in vitro and 
in vivo data, pairwise comparisons were carried out by performing nonparametric Mann-Whitney U-test 
and Wilcoxon test, respectively. he signiicance level was ixed at P = 0.05 with a power of 95%. All 
statistical tests were two-sided.
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